RAB37 and prostate adenocarcinoma: Furthermore, immunofluorescence analysis of clinical tumours samples in humans showed markedly decreased RAB37 expression in prostate adenocarcinomas, prostate transitional cell carcinomas, stomach adenocarcinoma and cervical squamous cell carcinomas (Supplementary Fig. S3a-c).